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Disease activity (SLEDAI)Abstract Aim of the work: The aim of this study was to assess adrenomedullin level in systemic
lupus erythematosus (SLE) patients with nephritis compared with those without and healthy con-
trols and to correlate adrenomedullin level with SLE disease activity.
Patients and methods: Serum adrenomedullin was evaluated in 60 SLE patients (mean age
27.7 ± 8.25 years) and in 20 matched controls. The SLE patients were divided into two groups:
Group I (with nephritis) and Group II (without) (30 patients each). The SLE disease activity index
(SLEDAI) was assessed.
Results: The median serum adrenomedullin levels were signiﬁcantly higher in SLE patients
(7.4 ng/ml) compared to healthy controls (3.1 ng/ml) (p< 0.001). It showed a statistically signiﬁ-
cant difference between group I (8.8 ng/ml) and II (6.1 ng/ml) (p< 0.01). A signiﬁcant relation
was observed between the level of serum adrenomedullin with the neuropsychiatric manifestations
(p= 0.006) and vasculitic lesions (p= 0.014) in group II patients and with pulmonary hypertension
(p= 0.04), oral ulcers (p= 0.03), and serositis (p= 0.02) in group I. A signiﬁcant negative corre-
lation was found in group I patients between adrenomedullin and 24 h protein/day (r= 0.38,
p< 0.05), as well as platelets & C4, and with C3 in group II as well as a highly signiﬁcant corre-
lation between SLEDAI and adrenomedullin level in SLE patients (r= 0.76, p< 0.001) and
steroid dose (p< 0.001).
Conclusion: Serum AM is elevated in SLE especially in lupus nephritis patients & correlates with
lupus disease activity. It is negatively associated with urine protein excretion per 24 h in the group of
lupus nephritis patients. Serum AM may be considered among biological markers in SLE.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).267659.
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Lupus nephritis is one of the most severe forms of organ
involvement in systemic lupus erythematosus (SLE) and occurs
in at least 50% of patients [1]. Key factors play a considerable
role in the pathogenesis of SLE as oxidative stress [2], apopto-
sis [3] and cytokine overproduction [4–7]. Current evidence
suggests that dysregulated expression of cytokines plays a
crucial role in the immunopathogenesis of SLE with a predom-
inantly type 1 T-helper cell (Th1) activation in patients with
active lupus nephritis [1].
A number of biochemical markers are currently used to
clinically assess SLE renal disease activity, such as
anti-double stranded deoxyribonucleic acid (ds-DNA)
antibodies and complement component levels. Nevertheless,
the correlation between these markers and lupus nephritis is
imperfect, and their utility in reﬂecting disease activity remains
controversial [8].
The importance of measuring vascular biomarkers as
Adrenomedullin reﬂects the fact that the molecule is released
by endothelial cells injury [9]. Adrenomedullin (AM) is a 52
amino acid peptide originally isolated from extracts of human
pheochromocytoma tissue and it belongs to the calcitonin/
calcitonin gene-related peptide (CGRP) family [10]. Pro-
inﬂammatory cytokines especially interleukin-1 (IL-1), IL-6
and tumor necrosis factor-alpha (TNF-a), which are pivotal
in mediating the inﬂammatory process of SLE, appear to stim-
ulate the production of AM in various cell types in SLE [11]. In
lupus nephritis, the presence of IL-1, IL-6 and TNF-a in dis-
eased kidney appears to mediate local pathogenic effects such
as mesangial proliferation [12]. It has been shown that AM
suppresses the secretion of pro-inﬂammatory cytokines such
as TNF-a in macrophage cell line so that they can suppress
mesangial cell mitogenesis [13]. Neuropeptides as AM can
exhibit potent anti-inﬂammatory activities. They can regulate
different critical levels of innate immunity [14]. The capacity
of these neuropeptides to regulate adaptive immunity has been
reported. They can impair activation/differentiation of Th1
cells [15].
The aim of this study was to assess adrenomedullin level in
SLE patients with nephritis compared with those without and
healthy controls, and to correlate its level with disease activity.2. Patients and methods
Sixty SLE patients were recruited from the outpatient and inpa-
tient units of Rheumatology and Rehabilitation Department,
Faculty of Medicine, Cairo University Hospitals, and were
diagnosed according to American College of Rheumatology
(ACR) revised criteria [16]. Twenty healthy subjects, matched
for age and sex included in the study served as a control group.
The patients were classiﬁed according to renal SLEDAI score
into 2 groups; Group I comprised 30 SLE patients with lupus
nephritis (having a renal SLEDAI of P8; at least 2 abnormal
results for renal parameters on at least two occasions) [17]
and group II comprised 30 SLE patients without nephritis.
The following conditions which may affect adrenomedullin
levels were excluded; uncontrolled systemic hypertension: sys-
tolic blood pressure (SBP) > 140 mmHg ± diastolic blood
pressure (DBP) > 90 mmHg, coronary heart disease orcongestive heart failure, end-stage renal failure, pregnancy,
chronic respiratory diseases, diabetes mellitus, chronic liver dis-
eases. Informed consents were taken from the patients and the
study was approved by the local ethics committee.
All the patients were subjected to full history taking, clinical
examination and Disease activity assessment using the
SLE disease activity index (SLEDAI) [18]; Mild activity
(SLEDAI; 1–10), Moderate activity (SLEDAI; 11–20), High
activity (SLEDAI; 21–45). Patients were subjected to labora-
tory investigations as follows: complete blood count (CBC),
erythrocyte sedimentation rate (ESR), Liver and kidney func-
tions, urine analysis, antinuclear antibodies (ANA), anti ds-
DNA, complement C3 (normal value: 90–180 mg/dl) and C4
(normal value: 10–40 mg/dl) tests. Adrenomedullin level was
tested in the sera of patients and controls using Enzyme
Linked Immunosorbent Assay (ELISA).
2.1. Serum adrenomedullin measurement
Blood samples from patients and controls were centrifuged
and stored at -80 C until assay of adrenomedullin. Sera were
analyzed by ELISA according to the manufacturer’s protocols
(ELISA kit, Cat No: EIA-3418, Lot: 601777, DRG
International Inc., USA).
Renal biopsy was performed in those patients with lupus
nephritis and classiﬁed according to the world health organiza-
tion (WHO) criteria [19].
Statistical analysis: Data obtained from the study were
coded and entered using the software SPSS (Statistical package
for social science) version 16.0. Quantitative parametric data
were described in mean and standard deviation (SD), while
non parametric data in median and percentiles. Percentages
were used when appropriate. Comparison between groups
was done using Chi square test for qualitative variables. For
quantitative data, comparison between 2 groups was done by
Mann–Whitney test for nonparametric data and among 3
groups by Kruskal Wallis test. The correlation between serum
adrenomedullin level and other biochemical data and SLEDAI
was assessed by Spearman coefﬁcient of correlation. ROC
curve was done to get the best cutoff to discriminate between
SLE nephritis versus non-nephritis and control and also to
get the best cutoff to discriminate between SLE patients with
activity 6 10 according to SLEDAI versus SLE patients with
more active disease > 10. Interpretation of the area under
the curve (AUC): 0.50–0.75 = fair, 0.75–0.92 = good,
0.92–0.97 = very good and 0.97–1.00 = excellent [20]. The
p-value is considered signiﬁcant if <0.05.3. Results
The SLE patients were 54 females (90%) and 6 males (10%),
their ages ranged from 13 to 51 years with mean age of
27.75 ± 8.25 years. The disease duration in all patients ranged
from 0.33 to 20 years with mean of 5.5 ± 4.5 years. The 20
matched control ages ranged from 16 to 40 years with a mean
of 29 ± 6.13 years.
On comparing between group I and II SLE patients as
regards the various demographic and clinical parameters, no
signiﬁcant difference was found apart from the SLEDAI score
that was signiﬁcantly higher in group I compared to group II
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patients showed a signiﬁcantly higher level of 24 h proteins
(p= 0.001) and serum creatinine (p= 0.03) as well as a lower
serum C3 (p= 0.01) compared to group II while no signiﬁcant
difference was observed in the other laboratory parameters
between the two groups. The clinical and laboratory character-
istics of the patients with and without nephritis are shown in
Table 1.
Serum adrenomedullin level was comparable between adult
(n= 47) and juvenile onset (n= 17 including 4 children) SLE
patients (p= 0.96). However, the level tended to be lower in
the children (8.5 ± 0.98 ng/dl) compared to the adult patients
(9.26 ± 10.5 ng/dl) (p= 0.6).
The median level of serum adrenomedullin was signiﬁcantly
higher in the SLE patients (7.43 ng/ml) compared to the con-
trols (6.1 ng/ml) and was higher in group I compared to group
II patients (Table 2, Fig. 1). The best cutoff of adrenomedullin
to discriminate between SLE nephritis versus SLE without
nephritis and control was 6.8 ng/dl, with an area under the
curve of 78% (p< 0.001, sensitivity 73% and speciﬁcity
78%) (Fig. 2). In group I patients, the serum adrenomedullin
level in group I patients tended to be higher in class IV patients
(n= 7) compared to those with other classes of renal biopsy
(II,III,V) (23 patients) but with no signiﬁcant statistical
difference (p= 0.84).Table 1 The clinical and laboratory characteristics of the systemic
Variable Systemic lupus erythemat
Group I (n= 30)
Age (years) 28.3 ± 7.6 (13–48)
Disease duration (years) 6.6 ± 4.8 (0.4–20)
Gender F:M 25:5
SLEDAI 13.8 ± 7.1 (2–30)
Clinical manifestations
Malar rash 17 (56.7)
Photosensitivity 13 (43.3)
Alopecia 12 (40)
Oral ulcers 12 (40)
Serositis 4 (13.3)
Arthritis 7 (23.3)
Neuropsychiatric 7 (23.3)
Vasculitis 3 (10)
Pulmonary hypertension 3 (10)
Laboratory feature
ESR (mm/h) 45.2 ± 34.3 (5–130)
Hb (g/dl) 11.3 ± 1.9 (7.7–14.4)
WBCs (·103/lL) 7.2 ± 3.1 (2.7–14.2)
Platelets (·103/lL) 257.6 ± 108.3 (67–571)
Creatinine (mg/dl) 0.6 ± 0.2 (0.3–1.1)
24hrs urine protein (g/d) 1.07 ± 1.3 (0–6.8)
Albumin (g/dl) 3.6 ± 0.7 (1.5–4.5)
C3 (mg/dl) 74.6 ± 28.3 (22–130)
C4 (mg/dl) 15.8 ± 11.1 (3–43.6)
Positive ANA 30 (100)
Positive Anti-ds DNA 24 (80)
Group I: Lupus nephritis patients, Group II: patients without lupus neph
ESR: erythrocyte sedimentation rate, Hb: hemoglobin, WBC: white bloo
double stranded DNA Results are presented as mean ± SD (range) or nA signiﬁcant correlation was observed between the level of
serum adrenomedullin with the neuropsychiatric manifesta-
tions (p= 0.006) and vasculitic lesions (p= 0.01) in group
II patients and with pulmonary hypertension (p= 0.04), oral
ulcers (p= 0.03), and serositis (p= 0.02) in group I.
Otherwise there were no statistically signiﬁcant correlations
with the other clinical features.
The serum adrenomedullin in all SLE patients signiﬁcantly
correlated with the ESR (p= 0.001), anti ds-DNA (p= 0.02)
and negatively with the hemoglobin content (p= 0.005), WBC
count (p= 0.01), C3 (p= 0.001) and C4 (p= 0.001) levels. It
is worth to mention that an insigniﬁcant correlation was found
between adrenomedullin and 24 h urine protein in all SLE
patients (r= 0.19, p= 0.13). A signiﬁcant negative correla-
tion was found with the platelets (p= 0.01), C4 (p= 0.008)
and 24 h protein in urine (p< 0.05) (0.03) in group I, while
with C3 (p= 0.03) in group II. Otherwise there were no statis-
tically signiﬁcant correlations with the other laboratory
parameters.
A signiﬁcant correlation was present between the serum
adrenomedullin level in SLE patients and the SLEDAI
(r= 0.76, p< 0.001). (Fig. 3). Moreover, a signiﬁcant correla-
tion of serum adrenomedullin and renal SLEDAI was present
in group I patients (r= 0.4, p= 0.02). The best cutoff of adre-
nomedullin to discriminate between patients with SLEDAI 6lupus erythematosus patients with and without nephritis.
osus patients (n= 60)
Group II (n= 30) P
27.2 ± 8.9 (14–51) 0.58
4.4 ± 3.9 (0.3–20) 0.06
29:1 0.64
7.4 ± 6.7 (2–27) <0.001
18 (60) 0.36
11 (36.7) 0.34
6 (20) 0.19
13 (43.3) 0.09
5 (16.7) 0.63
4 (13.3) 0.17
7 (23.3) 0.51
3 (10) 0.15
– –
51.0 ± 31.7 (5–150) 0.49
11.03 ± 1.9 (7–15) 0.68
5.65 ± 2.9 (2.1–15.5) 0.05
293.3 ± 103.9 (83–516) 0.19
0.5 ± 0.2 (0.1–0.9) 0.03
0.12 ± 0.13 (0–0.5) <0.001
3.8 ± 0.5 (3–4.9) 0.07
97.5 ± 32.2 (31.8–158) 0.01
18.8 ± 10.1 (3.77–45) 0.2
30 (100) –
15 (50) 0.36
ritis, FM: female to male ratio, SLEDAI: SLE disease activity index,
d cells, C: complement, ANA: antinuclear antibody, Anti-ds DNA:
umber (%). Bold values are signiﬁcant at p< 0.05.
Figure 2 Receiver Operating Curve (ROC) analysis showing the
diagnostic performance of serum adrenomedullin for discriminat-
ing systemic lupus erythematosus (SLE) patients with nephritis
from those without.
Table 2 Comparison of the median levels of serum adrenomedullin in systemic lupus erythematosus patients with (group I) and
without nephritis (group II) and the control.
Serum adrenomedullin
(ng/dl)
SLE patients (n= 60) Control
(n= 20)
p
Group I
(n= 30)
Group II
(n= 30)
Range 0.9–46.98 0.6–12 0.7–7.9
<0.001Median
25–75th
8.8
5.8–11.6
6.1
2.5–7.8
3.1
0.9–5.1
Group I: Lupus nephritis patients, Group II: patients without lupus nephritis. Bold values are signiﬁcant at p< 0.05.
Figure 1 Boxplot showing serum adrenomedullin levels in
systemic lupus erythematosus (SLE) patients with (group I) and
without nephritis (group II) and control.
S22 E. El-serougy et al.10 versus those with more active disease (>10) was 8.03 ng/dl
with an area under the curve of 91.7% (p< 0.001, sensitivity
78.6% and speciﬁcity 96.9%) (Fig. 4).
All patients received steroids, cyclophosphamide by 20,
antimalarials in 33, azathioprine in 29 and Mycophenolate
mofetil in 5 patients. Only the steroid dose was signiﬁcantly
higher in group I vs II patients (23.1 ± 11.9 and
14.3 ± 12.7 mg/d respectively) (p= 0.026). A signiﬁcant cor-
relation was found between adrenomedullin and steroid dose
(p< 0.001).
4. Discussion
Our study conﬁrmed that serum adrenomedullin levels were
signiﬁcantly higher in SLE patients compared to healthy con-
trols especially in patients with lupus nephritis. This agrees
with the results of other studies [9,11,21].
In the present work, serum adrenomedullin showed a good
diagnostic reliability in discriminating SLE patients with
nephritis from those without (sensitivity 73%, speciﬁcity
78%, cut-off value 6.8 ng/dl). In support to our results,
Kronenberg [22] reported that adrenomedullin showed greater
speciﬁcity (87.3%) and good discriminative capability for
patients who will experience progressive chronic kidney
disease.A non signiﬁcant relation was found between the serum
adrenomedullin level in lupus nephritis patients between class
IV and other classes. This is supported by a previous study
[11] that reported a similar behavior of adrenomedullin toward
mesangial and glomerular cells regardless of the histological
class of lupus nephritis.
In our study, relation of serum adrenomedullin level with
clinical manifestations of SLE patients showed a signiﬁcant
correlation with the neuropsychiatric manifestations
(p< 0.01) and vasculitic lesions (p< 0.01). This is compara-
ble to the ﬁndings of Yilmaz and co-workers [23] who reported
a threefold higher level of adrenomedullin in schizophrenic
patients compared to the level in the controls. The signiﬁcant
relation with vasculitic lesions is in agreement with another
study [24] that found an elevated adrenomedullin level in
patients with active giant cell arteritis.
An insigniﬁcant correlation was found between adrenome-
dullin and 24 h urine protein in SLE patients. A signiﬁcant
negative correlation was present only in those with lupus
nephritis. Similar results were reported by other authors [11]
who demonstrated an inverse relationship between plasma
adrenomedullin and proteinuria in SLE patients. This is sup-
ported by Plank et al. [25] who stated that exogenous
Figure 3 Correlation between adrenomedullin and systemic lupus erythematosus disease activity index (SLEDAI) in all SLE patients.
Figure 4 Receiver Operating Curve (ROC) analysis showing the
diagnostic performance of serum adrenomedullin for discriminat-
ing systemic lupus erythematosus (SLE) patients with activity >10
from those with mild activity.
Assessment of adrenomedullin level in SLE patients S23adrenomedullin infusion reduces mesangial cell number and
glomerular monocyte inﬁltration in the state of mesangial pro-
liferation during acute mesangioproliferative glomerulonephri-
tis and can inﬂuence its course.
This is further supported by a previous study [26] which
showed that adrenomedullin could suppress the proliferation
of rat glomerular mesangial cells, in addition it was found that
[27] mesangial cells grown in primary culture synthesize adre-
nomedullin, which is stimulated by TNF-a, IL-1b and hypoxic
conditions. Adrenomedullin increased cAMP levels in mesan-
gial cells leading to inhibition of their proliferation, migration,
reactive oxygen generation and macrophage inﬁltration. On
the other hand in another study [9] they found a signiﬁcantcorrelation between adrenomedullin and 24 h proteinuria in
all lupus patients.
In our study a highly signiﬁcant correlation was found
between SLEDAI and serum adrenomedullin level in SLE
patients. This coincides with the ﬁndings of previous studies
[9,11,21]. Moreover, adrenomedullin signiﬁcantly correlated
with the renal SLEDAI score and this coincides with the
results of Mak and co-workers [11].
In the present study, adrenomedullin signiﬁcantly correlated
with the steroid dose and this was conﬁrmed by other studies
[12,28,29]. In contrast, other authors [11] found no signiﬁcant
relation. They explained this ﬁnding by that; while corticos-
teroids may have a direct stimulatory effect on adrenomedullin
production, any suppression of disease activity might result in
decreased stimulation of adrenomedullin secretion.
There are several limitations with the current study. First,
not all renal biopsies were taken during the period of serum
adrenomedullin level measurement since they were performed
for clinical indications rather than for research purposes.
Second, it is a cross-sectional study and we were unable to cor-
relate the serum adrenomedullin level with various clinical
variables, before and after effective immunosuppressive treat-
ment. A longitudinal study on a larger population is recom-
mended and will undoubtedly augment the ﬁdelity of the
results.
In conclusion, it was conﬁrmed that adrenomedullin is ele-
vated in SLE especially in lupus nephritis patients, and corre-
lated with lupus disease activity. Negative association was
found between adrenomedullin and urine protein excretion
per day in lupus nephritis patients.Conﬂict of interest
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